文献速递冠心病血脂与心血管预防

LPA基因变异与他汀治疗患者的残余心血管风险相关

LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins.
PubMed 文献 · Circulation · 2018-01-01

研究通过两阶段全基因组关联分析,在电子病历与基因组学网络中发现LPA/PLG位点7个单核苷酸多态性与他汀治疗期间冠心病事件相关,最显著为rs10455872(OR 1.58,95%CI 1.35-1.86,P=2.6×10⁻¹⁰),并在复制队列中验证。该关联独立于他汀诱导的LDL-C变化,且在LDL-C≤70 mg/dL个体中持续存在,提示靶向脂蛋白(a)可能降低他汀患者的残余风险。

要点

  • LPA/PLG位点rs10455872与他汀治疗期间冠心病事件显著相关。
  • 该关联独立于他汀诱导的LDL-C降低,且在LDL-C≤70 mg/dL者中仍存在。
  • 结果支持探索靶向脂蛋白(a)以降低他汀患者残余心血管风险。

核心结论

  • LPA位点遗传变异与他汀治疗期间冠心病事件相关,且独立于LDL-C降低程度。

研究设计与样本

  • 两阶段全基因组关联研究:第一阶段纳入3099例他汀治疗期间发生冠心病事件者和7681例对照,来自电子病历与基因组学网络4个站点。
  • 第二阶段在第五个站点复制160例病例和1112例对照,并对最显著位点进行全表型关联研究。

主要发现

  • Meta分析发现LPA/PLG位点7个单核苷酸多态性达到全基因组显著性,与他汀治疗期间冠心病事件相关。
  • 最显著关联为LPA/PLG内含子单核苷酸多态性rs10455872(次要等位基因频率0.069;OR 1.58;95%CI 1.35-1.86;P=2.6×10⁻¹⁰)。
  • 复制队列中rs10455872与冠心病事件相关(OR 1.71;95%CI 1.14-2.57;P=0.009)。
  • 该关联独立于他汀诱导的LDL-C变化(OR 1.62;95%CI 1.17-2.24;P=0.004),并在LDL-C≤70 mg/dL个体中持续存在(OR 2.43;95%CI 1.18-4.75;P=0.015)。
  • 全表型关联研究支持该区域对冠心病的影响,未发现非心血管表型。

关键数值与推荐

  • 冠心病事件定义为急性心肌梗死或需冠状动脉血运重建。
  • 对照为在可比他汀治疗强度与时长下未发生冠心病事件者。

临床怎么用

  • 对于他汀治疗患者,LPA/PLG位点变异(如rs10455872)可能提示残余冠心病风险,独立于LDL-C降低。
  • 该发现支持探索靶向循环脂蛋白(a)浓度的策略以降低他汀患者的冠心病事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Coronary heart disease (CHD) is a leading cause of death globally. Although therapy with statins decreases circulating levels of low-density lipoprotein cholesterol and the incidence of CHD, additional events occur despite statin therapy in some individuals. The genetic determinants of this residual cardiovascular risk remain unknown. METHODS: We performed a 2-stage genome-wide association study of CHD events during statin therapy. We first identified 3099 cases who experienced CHD events (defined as acute myocardial infarction or the need for coronary revascularization) during statin therapy and 7681 controls without CHD events during comparable intensity and duration of statin therapy from 4 sites in the Electronic Medical Records and Genomics Network. We then sought replication of candidate variants in another 160 cases and 1112 controls from a fifth Electronic Medical Records and Genomics site, which joined the network after the initial genome-wide association study. Finally, we performed a phenome-wide association study for other traits linked to the most significant locus. RESULTS: The meta-analysis identified 7 single nucleotide polymorphisms at a genome-wide level of significance within the LPA/PLG locus associated with CHD events on statin treatment. The most significant association was for an intronic single nucleotide polymorphism within LPA/PLG (rs10455872; minor allele frequency, 0.069; odds ratio, 1.58; 95% confidence interval, 1.35-1.86; P=2.6×10-10). In the replication cohort, rs10455872 was also associated with CHD events (odds ratio, 1.71; 95% confidence interval, 1.14-2.57; P=0.009). The association of this single nucleotide polymorphism with CHD events was independent of statin-induced change in low-density lipoprotein cholesterol (odds ratio, 1.62; 95% confidence interval, 1.17-2.24; P=0.004) and persisted in individuals with low-density lipoprotein cholesterol ≤70 mg/dL (odds ratio, 2.43; 95% confidence interval, 1.18-4.75; P=0.015). A phenome-wide association study supported the effect of this region on coronary heart disease and did not identify noncardiovascular phenotypes. CONCLUSIONS: Genetic variations at the LPA locus are associated with CHD events during statin therapy independently of the extent of low-density lipoprotein cholesterol lowering. This finding provides support for exploring strategies targeting circulating concentrations of lipoprotein(a) to reduce CHD events in patients receiving statins.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Wei WQ, Li X, Feng Q, et al. LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins. Circulation. 2018. PMID: 29703846. doi:10.1161/CIRCULATIONAHA.117.031356

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。